State Board of Administration of Florida Retirement System Has $24.22 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

State Board of Administration of Florida Retirement System lowered its position in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) by 2.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 315,326 shares of the medical equipment provider’s stock after selling 8,004 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Hologic were worth $24,223,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Fieldpoint Private Securities LLC boosted its position in Hologic by 61.4% during the 1st quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. Hudock Inc. boosted its position in Hologic by 1,825.0% during the 1st quarter. Hudock Inc. now owns 385 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 365 shares during the last quarter. FinTrust Capital Advisors LLC bought a new stake in shares of Hologic during the 1st quarter worth approximately $45,000. Quent Capital LLC bought a new stake in shares of Hologic during the 4th quarter worth approximately $51,000. Finally, Rosenberg Matthew Hamilton bought a new stake in shares of Hologic during the 1st quarter worth approximately $55,000. Institutional investors and hedge funds own 92.70% of the company’s stock.

Hologic Stock Up 0.3 %

HOLX opened at $71.40 on Friday. Hologic, Inc. has a 1-year low of $66.58 and a 1-year high of $81.04. The stock’s fifty day simple moving average is $71.14 and its 200 day simple moving average is $72.79. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57. The stock has a market cap of $17.83 billion, a PE ratio of 12.04, a price-to-earnings-growth ratio of 0.81 and a beta of 1.05.

Hologic (NASDAQ:HOLXGet Rating) last posted its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.26. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $896.71 million. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The company’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.33 EPS. As a group, research analysts expect that Hologic, Inc. will post 5.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of analyst reports. UBS Group initiated coverage on Hologic in a research note on Wednesday, July 20th. They set a “neutral” rating and a $73.00 price objective on the stock. Citigroup dropped their price objective on Hologic from $78.00 to $75.00 in a research note on Thursday, April 28th. Bank of America cut Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $81.00 to $75.00 in a research note on Wednesday, July 20th. Wells Fargo & Company cut Hologic from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $90.00 to $75.00 in a research note on Monday, April 25th. Finally, Morgan Stanley dropped their price objective on Hologic from $72.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 28th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $76.71.

Insiders Place Their Bets

In other Hologic news, insider Jan Verstreken sold 6,500 shares of the stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total transaction of $512,200.00. Following the transaction, the insider now owns 64,191 shares in the company, valued at approximately $5,058,250.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.54% of the company’s stock.

Hologic Company Profile

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXGet Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.